Her scientific publications have appeared in the journals, Multiple Sclerosis Clinical and Laboratory Research, and Alternative Medicine Review. Formerly she worked in the care of the elderly and those with chronic disease in transitional care facilities. In the past 12 years she has been active in the advancement of new treatments for Multiple Sclerosis and related disease states.
Elaine has developed and patented treatments for MS, Depression and Bipolar Depressive Disorder, and Autism Spectrum Disorder. She has lectured throughout the United States and Canada to patients, doctors and pharmacists on issues of medical research and study application. She is the CEO and founder of two medical research companies, EDMS LLC and MedDEV Inc.
Ms. DeLack’s passion for research was spurred by her need to find something to help herself, in that she was diagnosed with MS when she was 30 years of age (1988). Mainstream medicine’s recognized treatments at the time of her diagnosis, proved to have no benefit for her condition.
Ms. DeLack went back to school and completed a course in clinical research. She dissected her symptoms by working backwards looking for a common factor in the various cellular chemical pathways that could be implicated in the etiology of all of her symptoms. She found the common factor to be histamine, specifically histamine2. Ms. DeLack has furthered her research which has unveiled the etiology of the histamine2 deficiency to be a decrease in the activity of monoamine oxidase-A (MAO-A), a mitochondrial enzyme in the brain, liver, adrenal and pancreas glands. MAO-A is vulnerable to numerous environmental factors such as stress, high estrogen, lipid peroxidation and toxins such as mercury and aluminum, lipid peroxidation. She has found this research to be applicable to MS, Autism, Depression, Bipolar Disorder, and Alzheimer’s.